Abstract：
A number of pharmacological targets are exploited to modify the parameters in the Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the foundation for the medical management of glaucoma, the evolution of which, until only recently, has been in relative stagnation. A burst of innovation has produced new ocular hypotensive drugs and long-acting delivery methods, including intracameral delivery, which are expanding the clinician\'s medical armamentarium. A number of IOP-independent neuroprotection strategies have shown strong potential in animal models of glaucoma, but translational attempts have been surprisingly limited. However, while pharmacological options are expanding, the traditional role of topical medical therapy is being challenged by selective laser trabeculoplasty, micro-invasive glaucoma surgery, and sustained delivery methods. A scientifically rigorous assessment of new treatments will be critical to empower clinicians with evidence-based information to optimise vision preservation and quality of life outcomes for their patients.
摘要：
利用许多药理学靶标来修改Goldmann方程中的参数并降低眼内压(IOP)。这一战略构成了青光眼医疗管理的基础，其中的演变，直到最近,一直处于相对停滞状态。一阵创新产生了新的降眼压药和长效给药方法,包括前房内分娩，正在扩大临床医生的医疗设备。许多非眼压依赖性神经保护策略在青光眼动物模型中显示出强大的潜力。但是翻译的尝试令人惊讶地受到限制。然而,虽然药理学选择正在扩大，局部药物治疗的传统作用正受到选择性激光小梁成形术的挑战，微创青光眼手术，和持续交付方法。对新疗法进行科学严格的评估对于赋予临床医生以循证信息以优化患者的视力保护和生活质量至关重要。
